in this activity, participants should be able to:
Explore the burden of diabetes in patients with hypertension and renal disease.
Identify cardiovascular risk factors in patients with diabetic nephropathy
Review strategies for the reduction of cardiovascular and renal risk factors in high-risk populations.
Describe the pathophysiologic basis for the use of ARBs vs ACE inhibitors
Evaluate the implications of recent clinical trial findings as they relate to patient care
George L. Bakris, MD
Vice Chairman, Department of Preventive Medicine
Rush-Presbyterian-St. Luke's Medical Center Professor of Preventive Medicine and Internal Medicine
Rush Medical College
Barry M. Brenner, MD
Samuel A. Levine Professor of Medicine
Harvard Medical School
Director Emeritus, Renal Divison Brigham and Women's Hospital
Janice G. Douglas, MD
Professor of Medicine
Chief, Division of Hypertension
University Hospitals of Cleveland and
Case Western Reserve University School of Medicine
Thomas D. Giles, MD
Professor of Medicine
Director of Cardiovascular Research
Division of Cardiology
Louisiana State University School of Medicine
New Orleans, Louisiana
Matthew R. Weir, MD
Professor of Medicine
Department of Medicine
Director, Division of Nephrology and Clinical Research Unit
University of Maryland School of Medicine
Patients with diabetes are at high risk for both microvascular and macrovascular complications. Microalbuminuria has been shown to be an independent predictor of morbidity and mortality associated with cardiovascular disease, and high albumin excretion has been shown to be independently related to left ventricular hypertrophy. This relationship suggests that albuminuria and cardiac damage occur in parallel. Hypertension is a common comorbidity in patients with type 2 diabetes and is an independent risk factor for vascular and renal complications.
This activity is accredited by the Health Science
Center for Continuing Medical Education (HSCCME)
to sponsor continuing medical education for physicians.
Health Science Center for Continuing Medical Education
designates this educational activity for a
maximum of 2.25 hours in category 1 credit toward
the AMA Physician's Recognition Award. Each physician
should claim only those hours he/she spent in
the educational activity.
Post-test and evaluation form are at
this link, but you must listen to
all four talks from this symposium
prior to completing the test.
This symposium will take an evidence-based approach to evaluating various therapeutic interventions, including angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), based on their ability to improve outcomes in high-risk patients with hypertension and special populations within this group.
The target audience for this program includes nephrologists, hypertension specialists, and other health care professionals who manage patients with hypertension and diabetes.
In accordance with ACCME Standards for Commercial Support of Continuing Medical Education and HSC-CME Disclosure Policy for CME Activities, faculty members have been asked to disclose any relationship they may have with commercial supporters of this CME activity or with companies providing drugs, medical equipment, etc, that may have relevance to the content of their presentations. Such disclosure is intended to provide participants with sufficient information to evaluate whether any given presentation has been influenced by the faculty’s relationship(s) or financial interests with said companies.
DISCLOSURE STATEMENTS :
Has grants/research support, consultantships, honorariam or is a member of the speakers' bureau from: Abbott Laboratories, Aventis, Bristol-Myers Squibb Company, Forest Laboratories, Inc., Merck & Co. Inc. and Sankyo Co. Ltd.
Dr. Brenner: Has consultantships, honorariam or is a member of the speakers' bureau from: Amgen, AstraZeneca, Aventis, Bristol-Meyers Squibb Company, Merck & Co. Inc and Novartis AG.
Dr. Douglas: Has grants/research support, consultantships, honorariam or is a member of the advisory board from: AstraZeneca, Aventis, Bioval, Bristol-Meyers Squibb Company, Eli Lilly and Company, Forest Laboratories Inc., GlaxoSmithKline, Merck & Co. Inc., Monarch Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pharmacia, Sankyo, Solvay and Wyeth-Ayerst Pharmaceuticals.
Has grants/research support, consultantships or is a member of the speakers' bureau from: AstraZeneca, Boehringer-Ingelheim Pharmaceuticals, Inc., Forest Laboratories, Inc., Merck & Co, Inc., Novartis AG, Sankyo, Solvay and Takeda Pharmaceuticals.
has indicated no significant financial interests or affiliations.
This activity may include information regarding the off-label and/or investigational use(s) of various pharmacologic agents. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
DISCLOSURE OF UNLABELED USE ASN/HDCN (if applicable):
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of HSC-CME.